Caplin Point Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on August 07, 2025, recommended Final Dividend of Rs. 3 per equity share.
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.6 pts more than Nifty Smallcap 250 and 4.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Caplin Point Laboratories' Board has recommended a Final Dividend of Rs. 3 per equity share (150%) on shares of Rs. 2 face value for FY25, taking the total FY25 dividend to Rs. 6 per share (300%) when combined with the Rs. 3 interim dividend paid in June 2025. The dividend is subject to shareholder approval at the 34th AGM scheduled for September 22, 2025, with payment to be made on or before October 21, 2025. The Board also approved Q1 FY26 standalone and consolidated results, with consolidated revenue from operations rising 11.2% YoY to Rs. 510.22 Cr and PAT growing 20.7% YoY to Rs. 150.76 Cr. EBITDA margins expanded to 37.7% (vs 35.7% in Q1 FY25), and the company holds free cash reserves of Rs. 1,237 Cr with total liquid assets of Rs. 2,207 Cr.
Consistent dividend payout of Rs. 6 per share reflects healthy cash generation, supported by strong Q1 earnings growth and a robust cash position of over Rs. 2,200 Cr in liquid assets. The strong margin expansion and double-digit profit growth should be viewed positively by shareholders, though the dividend yield remains modest relative to the share price.